Related Experiment Video
Updated: Feb 15, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA
Dimitrios Psimadas1, Varvara Valotassiou1, Sotiria Alexiou1
1a Department of Nuclear Medicine , University Hospital of Larissa, School of Medicine, University of Thessaly , Larissa , Greece.
Abstract:
Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can "carry" the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa).
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Gene Therapy
Molecular Models
Molecular Orbital Theory II
Subviral Agents
Molecular Orbital Theory I

